U.S. CAN AUTHORIZE BA.4/5 SUBVARIANT-BASED COVID-19 BOOSTERS WITHOUT NEW CLINICAL TRIAL DATA -FDA OFFICIAL MARKS$PFE— *Walter Bloomberg (@DeItaone) June 30, 2022
U.S. CAN AUTHORIZE BA.4/5 SUBVARIANT-BASED COVID-19 BOOSTERS WITHOUT NEW CLINICAL TRIAL DATA -FDA OFFICIAL MARKS$PFE